nach oben

Erschienen in:

01.11.2015 | Original Paper

The effect of superoxide anion and hydrogen peroxide imbalance on prostate cancer: an integrative in vivo and in vitro analysis

verfasst von: Maiquidieli Dal Berto, Claudia Giuliano Bica, Gustavo Pereira de Sá, Fernanda Barbisan, Verônica Farina Azzolin, Felipe Rogalski, Marta Maria Medeiros Frescura Duarte, Ivana Beatrice Mânica da Cruz

Erschienen in: Medical Oncology | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

The epidemiological impact of SOD2 imbalance on prostate cancer (PC) risk associated with genetic variations has previously been studied. However, we found no previous studies clarifying the nature of SOD2 effects on prostate cancer. Here, we performed integrated in vivo and in vitro protocols that analyzed the association between Ala16Val-SOD2 polymorphism and prostate cancer aggressiveness at the time of diagnosis and evaluated the effect of the imbalance on PC proliferation using the DU-145 PC cell line treated with paraquat and porphyrin. In the pharmacological model, paraquat was used to increase superoxide anion levels and porphyrin was the SOD2 analog. The results confirmed the impact of superoxide–hydrogen peroxide imbalance on PC cell biology since porphyrin decreased cell proliferation and both treatments modulated antioxidant genes. Therefore, our results corroborate previous suggestions that alteration of redox status could be exploited therapeutically in the treatment of PC.

Oberley TD, Zhong W, Szweda LI, Oberley LW. Localization of antioxidant enzymes and oxidative damage products in normal and malignant prostate epithelium. Prostate. 2000;44(2):144–55.CrossRefPubMed

Chaiswing L, Bourdeau-Heller JM, Zhong W, Oberley TD. Characterization of redox state of two human prostate carcinoma cell lines with different degrees of aggressiveness. Free Radic Biol Med. 2007;43(2):202–15.CrossRefPubMed

Chaiswing L, Zhong W, Oberley TD. Increasing discordant antioxidant protein levels and enzymatic activities contribute to increasing redox imbalance observed during human prostate cancer progression. Free Radic Biol Med. 2014;67:342–52.PubMedCentralCrossRefPubMed

Bresciani G, da Cruz IB, González-Gallego J. Manganese superoxide dismutase and oxidative stress modulation. Adv Clin Chem. 2015;68:87–130.CrossRefPubMed

Oberley LW. Anticancer therapy by overexpression of superoxide dismutase. Antioxid Redox Signal. 2001;3(3):461–72.CrossRefPubMed

Pani G, Colavitti R, Bedogni B, Fusco S, Ferraro D, Borrello S. Mitochondrial superoxide dismutase: a promising target for new anticancer therapies. Curr Med Chem. 2004;11(10):1299–308.CrossRefPubMed

Oberley LW. Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother. 2005;59(4):143–8.CrossRefPubMed

Bresciani G, Cruz IB, de Paz JA, Cuevas MJ, González-Gallego J. The MnSOD Ala16Val SNP: relevance to human diseases and interaction with environmental factors. Free Radic Res. 2013;47(10):781–92.CrossRefPubMed

Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson’s disease. Biochem Biophys Res Commun. 1996;226(2):561–5.CrossRefPubMed

10.

Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics. 2003;13(3):145–57.CrossRefPubMed

11.

Taufer M, Peres A, de Andrade VM, de Oliveira G, Sá G, do Canto ME, et al. Is the Val16Ala manganese superoxide dismutase polymorphism associated with the aging process? J Gerontol A Biol Sci Med Sci. 2005;60(4):145–57.CrossRef

12.

Bica CG, de Moura da Silva LL, Toscani NV, da Cruz IB, Sá G, Graudenz MS, et al. MnSOD gene polymorphism association with steroid-dependent cancer. Pathol Oncol Res. 2009;15(1):19–24.CrossRefPubMed

13.

Sun GG, Wang YD, Lu YF, Hu WN. Different association of manganese superoxide dismutase gene polymorphisms with risk of prostate, esophageal, and lung cancers: evidence from a meta-analysis of 20,025 subjects. Asian Pac J Cancer Prev. 2013;14(3):1937–43.CrossRefPubMed

14.

Oskina NA, Ermolenko NA, Boyarskih UA, Lazarev A, Petrova VD, Ganov DI, et al. Associations between SNPs within antioxidant genes and the risk of prostate cancer in the Siberian region of Russia. Pathol Oncol Res. 2014;20(3):635–40.CrossRefPubMed

15.

Costa F, Dornelles E, Mânica-Cattani MF, Algarve TD, Souza Filho OC, Sagrillo MR, et al. Influence of Val16Ala SOD2 polymorphism on the in vitro effect of clomiphene citrate in oxidative metabolism. Reprod Biomed Online. 2012;24(4):474–81.CrossRefPubMed

16.

Margalit DN, Jordahl KM, Werner L, Wang X, Gwo-Shu LM, Penney KL, et al. Germ line variation in superoxide dismutase-2 (SOD2) and survival outcomes after radiation therapy for prostate cancer: results of a test and validation set analysis. Clin Genitourin Cancer. 2015;13(4):370–7.CrossRefPubMed

17.

Duan H, Zhang HJ, Yang JQ, Oberley LW, Futscher BW, Domann FE. MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. Antioxid Redox Signal. 2003;5(5):677–88.CrossRefPubMed

18.

Bus JS, Gibson JE. Paraquat: model for oxidant-initiated toxicity. Environ Health Perspect. 1984;55:37–46.PubMedCentralCrossRefPubMed

19.

Miriyala S, Spasojevic I, Tovmasyan A, Salvemini D, Vujaskovic Z, St Clair D, et al. Manganese superoxide dismutase, MnSOD and its mimics. Biochim Biophys Acta. 2012;1822(5):794–814.PubMedCentralCrossRefPubMed

20.

Sobin LH, Wittekind Ch. TNM classification of malignant tumours. 6th ed. Hoboken: Wiley; 2002.

21.

Barbisan F, de Motta J R, Trott A, Azzolin V, Dornelles EB, Marcon M, et al. Methotrexate-related response on human peripheral blood mononuclear cells may be modulated by the Ala16Val-SOD2 gene polymorphism. PLoS One. 2014;9(10):e107299.PubMedCentralCrossRefPubMed

22.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.CrossRefPubMed

23.

Cadoná FC, Cattanni MFMR, Machado AK, Oliveira RM, Flores ERS, Assmann CE, et al. Genomodifier capacity assay: a non-cell test using dsDNA molecules to evaluate the genotoxic/genoprotective properties of chemical compounds. Anal Methods. 2014;6:8559–68.CrossRef

24.

Spitz DR, Oberley LW. An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal Biochem. 1989;179(1):8–18.CrossRefPubMed

25.

Choi WS, Shin PG, Lee JH, Kim GD. The regulatory effect of veratric acid on NO production in LPS-stimulated RAW264.7 macrophage cells. Cell Immunol. 2012;280(2):164–70.CrossRefPubMed

26.

Jentzsch AM, Bachmann H, Fürst P, Biesalski HK. Improved analysis of malondialdehyde in human body fluids. Free Radic Biol Med. 1996;20(2):251–6.CrossRefPubMed

27.

Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 1994;233:346–57.CrossRefPubMed

28.

William-Faltaos S, Rouillard D, Lechat P, Bastian G. Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines. Anticancer Res. 2006;26(3A):2093–9.PubMed

29.

Mao C, Qiu LX, Zhan P, Xue K, Ding H, Du FB, et al. MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 subjects. J Cancer Res Clin Oncol. 2010;136(7):975–9.CrossRefPubMed

30.

Liwei L, Chunyu L, Ruifa H. Association between manganese superoxide dismutase gene polymorphism and risk of prostate cancer: a meta-analysis. Urology. 2009;74(4):884–8.CrossRefPubMed

31.

Ergen HA, Narter F, Timirci O, Isbir T. Effects of manganase superoxide dismutase Ala-9Val polymorphism on prostate cancer: a case-control study. Anticancer Res. 2007;27(2):1227–30.PubMed

32.

Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman JW, et al. Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis. 2008;29(12):2335–40.PubMedCentralCrossRefPubMed

33.

Wang S, Wang F, Shi X, Dai J, Peng Y, Guo X, et al. Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk—a meta-analysis. Eur J Cancer. 2009;45(16):2874–81.CrossRefPubMed

Titel: The effect of superoxide anion and hydrogen peroxide imbalance on prostate cancer: an integrative in vivo and in vitro analysis
verfasst von: Maiquidieli Dal Berto
Claudia Giuliano Bica
Gustavo Pereira de Sá
Fernanda Barbisan
Verônica Farina Azzolin
Felipe Rogalski
Marta Maria Medeiros Frescura Duarte
Ivana Beatrice Mânica da Cruz
Publikationsdatum: 01.11.2015
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 11/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-015-0700-1

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The effect of superoxide anion and hydrogen peroxide imbalance on prostate cancer: an integrative in vivo and in vitro analysis

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2015

Cholangiocarcinoma: from molecular biology to treatment

IL-37 mediates the antitumor activity in renal cell carcinoma

DNA repair system and renal cell carcinoma prognosis: under the influence of NBS1

Loss of heterozygosity for chromosomal regions 15q14-21.1, 17q21.31, and 13q12.3-13.1 and its relevance for prostate cancer

A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors

Radiotherapy combined docetaxel and oxaliplatin chemotherapy is effective in patients with locally advanced nasopharyngeal carcinoma

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie